Accounts Payable, Current of ZyVersa Therapeutics, Inc. from 31 Dec 2022 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Summary: ZyVersa Therapeutics, Inc. quarterly Accounts Payable, Current in USD history and change rate from 31 Dec 2022 to 30 Sep 2025.
ZyVersa Therapeutics, Inc. Accounts Payable, Current for the quarter ending 30 Sep 2025 was $9,805,129, a 5.6% increase year-over-year.
Source SEC data: View on sec.gov

Accounts Payable, Current, Quarterly (USD)

Accounts Payable, Current, YoY Quarterly Change (%)

ZyVersa Therapeutics, Inc. Quarterly Accounts Payable, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$9,805,129	+$520,498	+5.6%	30 Sep 2025	10-Q	19 Nov 2025	2025	Q3
Q2 2025	$9,774,230	+$1,457,724	+18%	30 Jun 2025	10-Q	13 Aug 2025	2025	Q2
Q1 2025	$9,604,568	+$1,476,822	+18%	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q4 2024	$9,337,267	+$905,684	+11%	31 Dec 2024	10-Q	19 Nov 2025	2025	Q3
Q3 2024	$9,284,631	+$387,097	+4.4%	30 Sep 2024	10-Q	14 Nov 2024	2024	Q3
Q2 2024	$8,316,506	+$172,473	+2.1%	30 Jun 2024	10-Q	09 Aug 2024	2024	Q2
Q1 2024	$8,127,746	+$1,746,660	+27%	31 Mar 2024	10-Q	15 May 2024	2024	Q1
Q4 2023	$8,431,583	+$2,405,938	+40%	31 Dec 2023	10-K	27 Mar 2025	2024	FY
Q3 2023	$8,897,534			30 Sep 2023	10-Q	14 Nov 2023	2023	Q3
Q2 2023	$8,144,033			30 Jun 2023	10-Q	21 Aug 2023	2023	Q2
Q1 2023	$6,381,086			31 Mar 2023	10-Q	12 May 2023	2023	Q1
Q4 2022	$6,025,645			31 Dec 2022	10-K	25 Mar 2024	2023	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.